This distinct kinase inhibition profile may contribute to its potent effects observed in our ESCC models, potentially offering a therapeutic advantage in tumors driven primarily by JAK2 hyperactivation or those with specific dependencies on FLT3 signaling. This evidence concerns the gene FLT3 and esophageal squamous cell carcinoma.